213 related articles for article (PubMed ID: 33155587)
1. Selection of threose nucleic acid aptamers to block PD-1/PD-L1 interaction for cancer immunotherapy.
Li X; Li Z; Yu H
Chem Commun (Camb); 2020 Dec; 56(93):14653-14656. PubMed ID: 33155587
[TBL] [Abstract][Full Text] [Related]
2. Selection of PD1/PD-L1 X-Aptamers.
Wang H; Lam CH; Li X; West DL; Yang X
Biochimie; 2018 Feb; 145():125-130. PubMed ID: 28912094
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Gao T; Mao Z; Li W; Pei R
J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
[TBL] [Abstract][Full Text] [Related]
4. Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer.
Nakhjavani M; Shigdar S
Pharmacol Res; 2022 Jan; 175():106019. PubMed ID: 34861397
[TBL] [Abstract][Full Text] [Related]
5. Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy.
Li C; Zhang N; Zhou J; Ding C; Jin Y; Cui X; Pu K; Zhu Y
Cancer Immunol Res; 2018 Feb; 6(2):178-188. PubMed ID: 29217732
[TBL] [Abstract][Full Text] [Related]
6. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
7. Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
Patel J; Crawford JM
Biochemistry; 2018 Feb; 57(6):901-903. PubMed ID: 29350031
[No Abstract] [Full Text] [Related]
8. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
9. In vitro selection of an XNA aptamer capable of small-molecule recognition.
Rangel AE; Chen Z; Ayele TM; Heemstra JM
Nucleic Acids Res; 2018 Sep; 46(16):8057-8068. PubMed ID: 30085205
[TBL] [Abstract][Full Text] [Related]
10. Silencing PD-1 and PD-L1: the potential of PolyPurine Reverse Hoogsteen hairpins for the elimination of tumor cells.
Ciudad CJ; Medina Enriquez MM; Félix AJ; Bener G; Noé V
Immunotherapy; 2019 Apr; 11(5):369-372. PubMed ID: 30786843
[No Abstract] [Full Text] [Related]
11. In Vitro Selection of an ATP-Binding TNA Aptamer.
Zhang L; Chaput JC
Molecules; 2020 Sep; 25(18):. PubMed ID: 32933142
[TBL] [Abstract][Full Text] [Related]
12. Discovery of hPRDX5-based peptide inhibitors blocking PD-1/PD-L1 interaction through in silico proteolysis and rational design.
Zou S; Liu J; Sun Z; Feng X; Wang Z; Jin Y; Yang Z
Cancer Chemother Pharmacol; 2020 Jan; 85(1):185-193. PubMed ID: 31745591
[TBL] [Abstract][Full Text] [Related]
13. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
[TBL] [Abstract][Full Text] [Related]
15. PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade.
Hirsch L; Zitvogel L; Eggermont A; Marabelle A
Br J Cancer; 2019 Jan; 120(1):3-5. PubMed ID: 30413824
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
Tu X; Qin B; Zhang Y; Zhang C; Kahila M; Nowsheen S; Yin P; Yuan J; Pei H; Li H; Yu J; Song Z; Zhou Q; Zhao F; Liu J; Zhang C; Dong H; Mutter RW; Lou Z
Mol Cell; 2019 Jun; 74(6):1215-1226.e4. PubMed ID: 31053471
[TBL] [Abstract][Full Text] [Related]
17. Aptamers Targeting the PD-1/PD-L1 Axis: A Perspective.
Bertrand P
J Med Chem; 2023 Aug; 66(16):10878-10888. PubMed ID: 37561598
[TBL] [Abstract][Full Text] [Related]
18. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy.
Liu C; Zhou F; Yan Z; Shen L; Zhang X; He F; Wang H; Lu X; Yu K; Zhao Y; Zhu D
Br J Pharmacol; 2021 Jul; 178(13):2651-2670. PubMed ID: 33768523
[TBL] [Abstract][Full Text] [Related]
20. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
